The Filing Desk

Marker Therapeutics vs Upstream Bio

Marker Therapeutics MRKR · Upstream Bio UPB · Pharmaceuticals

Marker Therapeutics reported revenue of $4 million in fiscal 2025, 1.2 times Upstream Bio's $3 million in fiscal 2025. Marker Therapeutics' revenue fell 46.2% in its latest year, and Upstream Bio's grew 20.4%. Marker Therapeutics had an operating margin of -363.4%, against -5618.8% at Upstream Bio.

Side by side

Marker TherapeuticsUpstream Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4M$3M
Revenue growth−46.2%20.4%
Revenue growth a year, last 5 years47.6%—
Gross margin——
Operating margin−363.4%−5,618.8%
Net margin−343.0%−5,026.0%
Free cash flow—−$133M
Free cash flow margin—−4,675.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count70.5%293.6%
Last close$1.32$2.00
P/E at the last close——
Insider trades, last 12 months—sold $104,799
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Marker TherapeuticsUpstream Bio
Operating margin
Percent of revenue
Marker TherapeuticsUpstream Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Marker TherapeuticsUpstream Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Marker Therapeutics and Upstream Bio pages.